

DuPont Nutrition Biosciences ApS

CVR-no. 11350356
Langebrogade 1
1411 København K

Annual Report for the period 1 January 2015 - 31 December 2015

The Annual Report has been presented and adopted at the Annual General Meeting
of the Company on 30 May 2016.



Chairman
Henrik Fastholm

Table of contents

	Page
Company Information	3
Financial Highlights	4
Management's Review	5
Management's Statement	8
Independent Auditors' Report	9
Income Statement	10
Balance Sheet	11
Statement of Changes in Equity	13
Notes to the Annual Report	14

Company Information

The Company

DuPont Nutrition Biosciences ApS
Langebrogade 1
1411 Copenhagen K
CVR-no. 11350356

Board of Directors

Matthias Josef Heinzl, Chairman
Etienne Jean-Emmanuel Laurent
Henrik Arent Fastholm
Flemming Jørgensen
Flemming Kristensen, Elected by the employees
Anne Agger Sparsø, Elected by the employees

Executive Board

Matthias Josef Heinzl
Angela Taha Naef
Etienne Jean-Emmanuel Laurent
Henrik Arent Fastholm

Auditors

PricewaterhouseCoopers
Statsautoriseret Revisionspartnerselskab
Strandvejen 44
DK-2900 Hellerup

Financial Highlights

(DKKm)	2015	2014	2013	2012	2011
					(8 months)
Income Statement					
Revenue	3,693	3,422	3,346	3,279	1,978
Operating profit	380	193	423	278	(218)
Income from investments in subsidiaries	268	(20)	90	950	5,276
Net financials	(59)	26	(5)	(20)	(269)
Profit for the period	497	233	489	1,151	4,951
Balance Sheet					
Balance sheet total	13,336	11,716	11,426	12,712	14,572
Investment in tangible fixed assets	111	53	78	70	49
Equity	6,336	5,839	5,606	5,117	6,506
Number of employees	1,191	1,205	1,243	1,247	1,320
Key Figures in %					
Profit margin	10.3	5.6	12.6	8.5	(11.0)
Return on net assets	2.8	1.6	3.7	2.2	(1.5)
Solvency ratio	47.5	49.8	49.1	40.3	44.6
Return on equity	8.3	4.1	9.1	19.8	54.9

For definitions, please refer to accounting policies

Management's Review

Market overview

DuPont Nutrition Biosciences ApS is an indirectly owned subsidiary of the E.I DuPont de Nemours and Company and sells bio-based ingredients for the use in food and beverages and industrial enzymes to a wide range of industries.

The majority of the products are sold on the European market and are products within the Health & Nutrition division. This Division sell cultures, emulsifiers, gums & systems, and natural sweeteners, which are mainly used in dairy products, baking, ice cream, beverages, confectionery, dietary supplements and chewing gum.

Further DuPont Nutrition Biosciences ApS has activities within Research and Development, Production, Distribution and a range of administrative functions. The management of the Nutrition & Health division and the European sales organisation (SAFI) are based in DuPont Nutrition Biosciences ApS.

On the production sites placed in Grindsted and Haderslev we manufacture products within emulsifiers, standardised textural ingredients, cultures, pharmaceuticals, functional systems and enzymes (mainly for the milling and bakery industries).

DuPont Nutrition Biosciences ApS is the parent company for a number of subsidiaries and the owner of all IP rights within bio-based food ingredients developed by DuPont Nutrition Biosciences ApS and subsidiaries.

Innovation

Application, research and development activities in Denmark are placed at the site in Brabrand. DuPont Nutrition Biosciences ApS continually invest in process development to increase efficiencies, reduce manufacturing costs, water and energy use and CO2 emissions. Our innovation is strategically positioned to address the needs of industry and society in the face of the global challenges in food, health, energy and chemicals.

Application is part of DuPont Nutrition Biosciences ApS' innovation network, which is a global network of innovation activities including research and development, applications, technical customer service, and analysis. In application DuPont Nutrition Biosciences ApS' bio-based ingredients are tested and evaluated in different food applications to ensure optimal use and benefit. The food application areas include bakery, beverage, confectionery, brewing, dairy, frozen desserts, fruit, meat, poultry, seafood or oils and fats industrial products. Application also includes work within the general areas of food safety and health and nutrition across all industries.

The majority of applications is sales oriented (technical service and trouble shooting for the customers) based on known as well as perceived customer demands. Understanding our customers and their current and future needs is a crucial part of the innovation process as it enables us to select and prioritise the projects to invest in.

Development in the year

In 2015, DuPont Nutrition Biosciences ApS recorded revenue of DKK 3,693 million against DKK 3,422 million in 2014. The increase is mainly due to increased sales to Middle East, North America, and China.

Operating profit increased to DKK 380 million against 193 million in 2014. This is a result of the company's focus on increased sales, and reduced cost through efficient production, and fixed cost reduction programs.

At 31 December 2015 the equity was DKK 6,336 million against DKK 5,839 million last year.

Future development

The company's strategy for growth is to apply its science and technology to address challenges driven by global population growth. Applying science to deliver innovative solutions and new products in the marketplace generates shareholder value and profitable growth. The company continues to achieve fixed cost, working capital and variable cost productivity through disciplined business processes called DuPont Integrated Business Management (DIBM) and DuPont Production System (DPS).

Risks

In the ordinary course of business, the Group is exposed to a variety of financial risks that include commodity price risk, credit risk, liquidity risk and interest rate risk. The policies and procedures in relation to the monitoring of these risks are undertaken in conjunction with the ultimate parent undertaking, E.I. du Pont de Nemours and Company, which includes entering into contractual arrangements in order to limit the adverse effects on the Group's financial performance.

Management's Review

Corporate Social Responsibility

In DuPont, sustainability is at the core of what we do - from sustainable sourcing and manufacturing to creating market-facing sustainable solutions and addressing the global food challenges.

As the global population continues to grow, we face unprecedented challenges in sustainably addressing some of the world's toughest problems. Feeding the world, decreasing our dependence on fossil fuels, and protecting people and the environment are all critical issues that require long-term thinking and science-driven innovation. However, we recognize that we can't do this alone. Around the world, we are working with academia, governments, other companies and non-governmental organizations to deliver scientific innovations that lead to long-term, viable, sustainable solutions along our value chains.

DuPont's core values of Safety and Health, Environmental Stewardship, Highest Ethical Behaviour, and Respect for People are directly aligned with the principles set out in the UN Global Compact which DuPont became a signatory of in 2001. The core values reflect the way we work and how we operate every day - with our customers, with our partners from around the world, and in the communities in which we operate.

Key 2015 Accomplishment

DuPont has been named to the 2014 North America Dow Jones Sustainability Index (DJSI), one of the most respected socially responsible investment indices on the market. But in 2015 we made the strategic decision to no longer submit information to RobecoSAM and prioritize supplying information that is publically available like the CDP and WDP and assuring updated information is available on the Bloomberg terminals. Again in 2015, DuPont was honoured as a "Top 50 Company for Executive Women" by the National Association for Female Executives (NAFE). NAFE honor corporations that identify successful women by actively promoting environments where women lead businesses, set policy and make the decisions that affect their company's bottom line.

Policies and guidelines

In DuPont Nutrition Biosciences ApS, we focus on three key policies: The DuPont Code of Conduct, the Human Rights Policy and the Safety, Health and Environmental Policy. The policies serves as a resource guide to help all employees make decisions that reflect DuPont's core values. The policies also reinforce our commitment to sustainability and are important to our stakeholders.

The DuPont Code of Conduct sets expectations for every employee about how we are to operate our businesses, work with customers, suppliers and other business partners, serve our stakeholders, and interact with our communities and with each other.

DuPont employees are required to receive training in the Code yearly. In addition to the training in the Code, all employees completed minimum one other ethics and compliance module in 2015. The training modules are available online and a test is required to pass the training. We see the full completion of the training programme as a satisfactory result for the reporting period.

The Human Rights policy is based on the principles in the UN Global Compact. We commit to conduct our business in an ethical and responsible manner that supports and respects the protection of human rights. We will work to identify and do business with partners who aspire to conduct their business in a similar manner.

The Human Rights Policy is implemented through various means. In 2015, we continued our engagement in Sedex (Supplier Ethical data Exchange). Sedex is a management tool for ethical data that satisfies our needs to monitor our own sites against the human rights policy, perform risk assessment as well as meeting customers' requirements for transparency. Our manufacturing sites have completed the self-assessment questionnaire that focuses on labour standards as well as health and safety, environment and business practices. The DuPont Nutrition Biosciences ApS sites have conducted an ethical audit based on the SMETA (Sedex Members Ethical Trade Audit) procedure. The audit will be repeated every three years.

We also address human rights in the context of our sourcing. We expect our suppliers to comply with same high standards as our other partners. Suppliers are selected on a professional business basis, which includes consideration of the supplier's environmental and social responsibility. Our supplier approach supports our efforts described in the DuPont Code of Conduct, the Human Rights Policy and the Safety, Health and Environmental Policy. In 2014, we implemented a DuPont Supplier Code of Conduct which has been sent to our suppliers.

We also support impact reduction through participation in multi-stakeholder organisations such as the Roundtable on Sustainable Palm (RSPO) and the Roundtable on Responsible Soy Association (RTRS). In 2011, we achieved RSPO certifications at our emulsifier sites, and we are still one of the few companies that can offer RSPO certified sustainable emulsifiers from a segregated supply chain.

The Safety, Health and Environment policy is based on the principles of sustainable development. We are committed to meet legal, internal, and other requirements, to which we describe, to prevent pollution and preserve resources and to prevent injury and ill health of our employees.

DuPont is working to increase shareholder and societal value while striving for the goal of zero for all safety and environmental incidents. In 2015, DuPont Nutrition Biosciences ApS continued aligning safety and environmental management systems with DuPont to be able to commit to zero.

Management's Review

Throughout DuPont's manufacturing sites, we have applied management systems to assess, improve, and track environmental, health and safety performance of our own operations. The performance is reported to the DuPont Nutrition & Health leadership team quarterly and yearly to DuPont corporate.

Sustainability goals for DuPont Nutrition Biosciences ApS have been approved by the leadership team in 2013. The environmental goals are set up for energy, greenhouse gas emissions and water. In addition, a goal to achieve ISO 14001 certifications at all manufacturing sites by end 2015 have been set up. This goal has already been achieved by DuPont Nutrition Biosciences ApS. It would be mentioned that at the moment of writing, the 2020 goals are being updated to reflect an even stronger commitment to sustainability and notably sustainable solutions.

Life cycle thinking has improved the understanding of the role that food ingredients play in the reduction of adverse environmental impacts in customer applications or during consumer use of our customers' products. By end 2015, we have conducted peer-reviewed Life Cycle Assessments (LCAs) of 90% of our key products to gain insights into our products' environmental impacts and to drive improvements. By 2020, we will have completed LCAs within all of our major product categories.

Statutory Report on the underrepresented gender, cf. section 99b of the Danish Financial Statement Act

In 2013 the Company set goals for improving equal gender representation in management. The goals are to be achieved before 1 January 2017, and are as follows;

	Goal	2015
In the Board of Directors the minority shall at least represent	25%	0%
In management positions below the Board of Directors the minority shall at least represent	30%	40%

In the Board of Directors the goal was not achieved in 2015. Equal gender and diversity in general was considered in the 2015 appointment, and the most qualified person was appointed.

The Company has achieved equal representation of gender in the management level below the Board of Directors.

Going Forward

Seeking to have a sustainable value chain, from raw material sourcing to providing sustainable solutions, DuPont Nutrition Biosciences ApS achieves its vision of sustainability by increasing and enhancing the positive impacts of activities throughout the value chain. We see sustainability as a valuable business component and a driver for business growth, as well as a source of differentiation and a way of achieving competitive advantages.

Sustainability have been in the DNA of the company for many years, and our customers know that DuPont is at the forefront of trends, trust and rely on us, meaning that the company is well positioned in this market going forwards.

Future development

The Company expects continued increase in revenue from Middle East and China in 2016. Further cost reduction programs are to be implemented, and the company expects increased profit in 2016.

Subsequent events

The Company has in January 2016 decided to carry out a restructuring plan, which will reduce the number of employees by 8%, in an effort to further reduce fixed cost. No other major events have occurred that could considerably influence the economic position of the Company as at 31 December 2015.

Management's Statement

The Executive and Supervisory Boards have today considered and adopted the Annual Report of DuPont Nutrition Biosciences ApS for the financial year 1 January – 31 December 2015.

The Annual Report is prepared in accordance with the Danish Financial Statements Act.

In our opinion, the Financial Statements give a true and fair view of the financial position at 31 December 2015 of the Company and of the results of the Company operations for 2015.

We recommend that the Annual Report be adopted at the Annual General Meeting.

Copenhagen, 30 May 2016

Executive Board

Matthias Josef Heinzl

Angela Taha Naef

Henrik Arent Fastholm

Etienne Jean-Emmanuel Laurent

Board of Directors

Matthias Josef Heinzl
Chairman

Henrik Arent Fastholm

Flemming Jørgensen

Etienne Jean-Emmanuel Laurent

Anne Agger Sparso

Flemming Kristensen

Independent Auditor's Report

To the Shareholder of DuPont Nutrition Biosciences ApS

Report on the Financial Statements

We have audited the Financial Statements of DuPont Nutrition Biosciences ApS for the financial year 1 January – 31 December 2015, which comprise income statement, balance sheet, statement of changes in equity, notes and summary of significant accounting policies. The Financial Statements are prepared in accordance with the Danish Financial Statements Act.

Management's Responsibility for the Financial Statements

Management is responsible for the preparation of Financial Statements that give a true and fair view in accordance with the Danish Financial Statements Act, and for such internal control as Management determines is necessary to enable the preparation of Financial Statements that are free from material misstatement, whether due to fraud or error.

Auditor's Responsibility

Our responsibility is to express an opinion on the Financial Statements based on our audit. We conducted our audit in accordance with International Standards on Auditing and additional requirements under Danish audit regulation. This requires that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance whether the Financial Statements are free from material misstatement.

An audit involves performing audit procedures to obtain audit evidence about the amounts and disclosures in the Financial Statements. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the Financial Statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the Company's preparation of Financial Statements that give a true and fair view in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of accounting estimates made by Management, as well as evaluating the overall presentation of the Financial Statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

The audit has not resulted in any qualification.

Opinion

In our opinion, the Financial Statements give a true and fair view of the financial position of the Company at 31 December 2015 and of the results of the Company operations for the financial year 1 January - 31 December 2015 in accordance with the Danish Financial Statements Act.

Statement on Management's Review

We have read Management's Review in accordance with the Danish Financial Statements Act. We have not performed any procedures additional to the audit of the Financial Statements. On this basis, in our opinion, the information provided in Management's Review is consistent with the Financial Statements.

Copenhagen, 30 May 2016


PricewaterhouseCoopers

Statsautoriseret Revisionspartnerselskab

CVR No 33 77 12 31



Jesper Hansen
State Authorised Public Accountant



Thomas P. Blohm
State Authorised Public Accountant

Income Statement

(DKKm)	Note	2015	2014
Revenue	1	3,693	3,422
Cost of sales	5	(2,603)	(2,509)
Gross profit		1,090	913
Research and development expenses	5	(217)	(276)
Sales and distribution expenses	5	(566)	(527)
Administrative expenses	5, 6	(399)	(317)
Other operating income		743	630
Other operating expenses		(271)	(230)
Operating profit		380	193
Income from investments in subsidiaries	2	268	(20)
Financial income	3	157	107
Financial expenses	3	(216)	(81)
Profit before tax		589	199
Income tax	4	(92)	34
Profit for the period		497	233
Distribution of profit/(loss)			
Retained earnings		497	233
		497	233

Balance Sheet

ASSETS

(DKKkm)	Note	31 December 2015	31 December 2014
Fixed assets			
Intangible fixed assets	7		
Software		9	17
Patents, rights and licenses		264	339
Total		273	356
Tangible fixed assets			
	8		
Land and buildings		352	363
Plant and machinery		355	332
Fixtures, fittings, tools and equipment		26	30
Prepayments and fixed assets under construction		51	55
Total		784	780
Financial fixed assets			
Investments in subsidiaries	9	5,248	4,989
Investments in associates	9	13	-
Receivables from subsidiaries	9	72	123
Other investments and securities	9	5	5
Deferred tax assets	13	80	118
Other receivables		3	5
Total		5,421	5,240
Total fixed assets		6,478	6,376
Current assets			
Inventories	10	426	446
Receivables			
Trade receivables		228	217
Receivables from subsidiaries		2,657	2,339
Corporation tax		57	31
Other receivables		36	44
Prepayments	11	10	7
Total		2,988	2,638
Cash and cash equivalents		3,444	2,256
Total current assets		6,858	5,340
Total assets		13,336	11,716

Balance Sheet

LIABILITIES AND SHAREHOLDERS' EQUITY

(DKKm)	Note	31 December 2015	31 December 2014
EQUITY	12		
Company capital		954	954
Retained earnings		5,382	4,885
Total equity		6,336	5,839
NON-CURRENT LIABILITIES	14		
Deferred income	16	283	330
Total		283	330
CURRENT LIABILITIES	14		
Trade payables		314	326
Payables to subsidiaries		6,133	4,970
Other payables	15	223	204
Deferred income	16	47	47
Total		6,717	5,547
Total liabilities		7,000	5,877
Total liabilities and shareholders' equity		13,336	11,716
Contingent assets, liabilities and other financial obligations	17		
Related parties and ownership	18		
Accounting Policies	19		

Statement of Changes in Equity

(DKKm)	Company capital	Retained earnings	Total
Equity at 1 January 2015	954	4,885	5,839
Profit for the year		497	497
Total change in equity		497	497
Equity at 31 December 2015	954	5,382	6,336

Change in company capital	2015	2014	2013	2012	2011/11
Company capital, opening	954	954	954	954	954
Company capital, closing	954	954	954	954	954

Notes to the Annual Report

1 Revenue

(DKKm)	2015	2014
DuPont Nutrition & Health	3,399	3,154
DuPont Industrial Biosciences	294	268
Total	3,693	3,422
Denmark	150	176
EMEA*	2,617	2,443
North America	233	191
Latin America	365	323
Asia-Pacific	328	289
Total	3,693	3,422

*EMEA include revenue to customers in the Middle East, Africa and Europe excluding Denmark.

2 Income from investments in subsidiaries

Dividends from subsidiaries	8	28
Writedowns of financial assets	260	(48)
Total	268	(20)

3 Financial income and expenses

Financial income

Financial income from subsidiaries	25	24
Financial income from bank deposits	3	5
Financial income from other receivables	15	-
Income from other investments and securities	2	-
Exchange gains	112	78
Total	157	107

Financial expenses

Financial expenses relating to subsidiaries	(12)	(14)
Financial expenses relating to credit institutions etc.	(8)	(2)
Exchange losses	(196)	(65)
Total	(216)	(81)

Net financials	(59)	26
-----------------------	-------------	-----------

4 Income tax

Current tax on profit	(46)	(21)
Change in deferred tax	(29)	7
Other taxes	(5)	-
Adjustment of tax for previous years	(12)	48
Total	(92)	34

Notes to the Annual Report

5 Employee expenses

	2015	2014
Employee expenses		
Wages and salaries	(618)	(616)
Defined contribution plans	(50)	(52)
Other social security expenses	(9)	(11)
Total	(677)	(679)
Executive Board	13	12
Board of Directors	-	-
Total average number of employees		
Total average number of employees	1,191	1,205

6 Fees for auditors elected at the annual general meeting

Audit fee	(1)	(1)
Total	(1)	(1)

Notes to the Annual Report

7 Intangible fixed assets

(DKKm)	Software	Patents, rights and licenses	Total
Cost at 1 January 2015	287	915	1,202
Additions	-	-	-
Disposals	-	(30)	(30)
Transferred (to) from other items	-	-	-
Cost at 31 December 2015	287	885	1,172
Amortisation at 1 January 2015	(270)	(576)	(846)
Writedowns for the year	-	-	-
Amortisation of disposals during the year	-	17	17
Amortisation for the year	(8)	(62)	(70)
Amortisation at 31 December 2015	(278)	(621)	(899)
Carrying amount at 31 December 2015	9	264	273

8 Tangible fixed assets

(DKKm)	Land and buildings	Plant and machinery	Fixtures, fittings, tools and equipment	Prepayments and assets under construction	Total
Cost at 1 January 2015	934	1,265	358	55	2,612
Additions	12	47	6	46	111
Disposals	(11)	(15)	(14)	-	(40)
Transferred (to) from other items	10	35	5	(50)	-
Cost at 31 December 2015	945	1,332	355	51	2,683
Depreciation and writedowns at 1 January 2015	(571)	(933)	(328)	-	(1,832)
Depreciation of disposals during the year	10	15	13	-	38
Depreciation for the year	(32)	(59)	(14)	-	(105)
Depreciation and writedowns at 31 December 2015	(593)	(977)	(329)	-	(1,899)
Carrying amount at 31 December 2015	352	355	26	51	784

Notes to the Annual Report

9 Financial fixed assets

(DKK)m	Investments in subsidiaries	Investments in associates	Receivables from subsidiaries	Other investments and securities	Total
Cost at 1 January 2015	8,343	-	123	47	8,513
Additions	-	13	-	-	13
Disposals	(1)	-	(51)	-	(52)
Cost at 31 December 2015	8,342	13	72	47	8,474
Value adjustments at 1 January 2015	(3,354)	-	-	(42)	(3,396)
Reversal of writedowns	260	-	-	-	260
Writedowns	-	-	-	-	-
Disposals	-	-	-	-	-
Value adjustments at 31 December 2015	(3,094)	-	-	(42)	(3,136)
Carrying amount at 31 December 2015	5,248	13	72	5	5,338

Investments in subsidiaries are specified as follows

Name	Country	Ownership in % Currency	Share capital in currency ('000)	Dupont's share of equity in DKK ('000)	Dupont's share of profit for the year in DKK ('000)
Danisco Argentina S.A.	Argentina	98.9131 ARS	6,758	388,270	41,468
Eurotec SPRL	Belgium	100 EUR	19	170	-
Solae Alimentos	Brazil	26 BRL	499,045	74,046	13,159
Danisco Cultor Trading Ltda.	Brazil	99 BRL	6,116	889	-
Danisco Flexible Brazil Ltda	Brazil	99 BRL	103	117	-
Danisco Chile S.A.	Chile	99.9998 CLP	6,973,969	246,511	49,621
Danisco Colombia Ltda.	Colombia	99 COP	4,524,200	88,713	8,019
ApS Syntetic	Denmark	100 DKK	1,000	20,591	(17)
Cometra ApS	Denmark	100 DKK	15,000	23,889	(96)
Ydernæs 1 ApS	Denmark	100 DKK	700	13,914	2,076
Danisco Egypt Trading LLC	Egypt	99.9 EGP	50	17,073	4,170
Danisco Sweeteners Oy	Finland	100 EUR	20,000	753,042	32,271
Finnfeeds Finland Oy	Finland	100 EUR	1,346	228,698	52,924
Finnfeeds Oy Vaasa	Finland	100 EUR	9	1,087,551	21,730
Danisco France SAS	France	100 EUR	46,123	3,608,104	258,347
Danisco Centro America S.A.	Guatemala	99 GTQ	5	3,075	(1)
Danisco Guatemala S.A.	Guatemala	99.8 GTQ	50	(6,180)	629
Danisco Holland B.V.	Holland	100 EUR	20	190,193	(3,577)
Danisco India Pvt. Ltd.	India	99.9976 INR	405,579	126,693	4,387
Danisco Japan Limited	Japan	100 JPY	498,000	231,312	(10,517)
DuPont Nutrition Food Ingredients (Beijing) Co., Ltd.	China	100 CNY	86,104	(4,753)	4,776
Danisco (China) Holding co. Ltd.	China	100 CNY	230,285	691,432	2,842
Danisco Sweeteners (Anyang) Co., LTD	China	54 CNY	81,111	5,424	580
DuPont Nutrition and Biosciences Commercial, S.de R.L. de C.V.	Mexico	99.999 MXN	664	763,696	97,057
DuPont Nutrition and Biosciences Mexico, S. de R.L. de C.V.	Mexico	99.996 MXN	11	21,862	(2,742)
Danisco Peru S.A.C.	Peru	99.999 PEN	1,795	10,625	2,998
Danisco Poland Sp. z.o.o	Poland	100 PLN	200	14,087	5,342
Danisco Slovakia s.r.o.	Slovakia	100 EUR	7	(5,795)	(6,948)
DuPont Nutrition and Biosciences Iberica, S.L.	Spain	100 EUR	357	487,020	110,742
Danisco South Africa (Pty) Ltd	South Africa	100 ZAR	0	25,762	22,028
Danisco Dis Ticarat Limited Sirketi.	Tyrkey	99.5 TRY	5	23,421	6,888
Danisco Holdings (UK) Ltd.	UK	100 GBP	8,600	45,752	(321)
Genencor International Cayman Ltd	Cayman	100 USD	50	5,986,400	6,469
Danisco Ukraine LLC	Ukraine	100 UAH	844	22,952	4,797
Danisco Austria GmbH	Austria	99 EUR	305	463,699	8,088

Investments in associates are specified as follows

Inboise SA	Belgium	10.2 EUR	1,810	20,420	6,953
------------	---------	----------	-------	--------	-------

Notes to the Annual Report

10 Inventories

(DKKm)	31 December 2015	31 December 2014
Raw materials and consumables	135	137
Work in progress	108	107
Finished goods and goods for resale	183	202
Total	426	446
Inventories recognised at net realisable value	19	24

11 Prepayments

Prepaid IT licences	3	4
Prepaid rent	4	-
Other	3	3
Total	10	7

12 Equity

In 2012 the Company has changed into a Private Limited Company. The Company capital is unchanged and comprises of 47,693,295 shares of DKK 20.

13 Deferred tax asset

Specification of deferred tax

Intangible fixed assets	(20)	(7)
Tangible fixed assets	26	43
Current assets	(7)	1
Non-current liabilities	81	81
Total	80	118

14 Maturity analysis of financial liabilities

Ageing of contractual maturities

Within 1 year	6,717	5,547
Between 1 and 5 years	187	187
Over 5 years	96	143
Total	7,000	5,877

15 Other payables

Wages, salaries, holiday pay etc.	136	138
VAT and other taxes	56	44
Other items	31	22
Total	223	204

16 Deferred income

Non-current

Prepaid royalty	283	330
Total	283	330

Current

Prepaid royalty	47	47
Total	47	47

Notes to the Annual Report

17 Contingent assets, liabilities and other financial obligations

(DKKm)	31 December 2015	31 December 2014
Guarantees and other financial commitments	4	4
Total	4	4
Operating rental receivables		
Maturity of operating rental receivables		
Within 1 year	1	-
Between 1 and 5 years	2	2
Over 5 years	3	4
Total	6	6
Operating lease and rental liabilities		
Maturity of operating lease and rental liabilities		
Within 1 year	20	19
Between 1 and 5 years	68	59
Over 5 years	37	45
Total	125	123

Guarantees and other financial commitments

DuPont Nutrition Biosciences ApS has provided a guarantee for financial and other support to the subsidiary Danisco South Africa (Pty) Ltd to enable continual going concern.

Operating rental receivables and lease/rental liabilities

DuPont Nutrition Biosciences ApS solely has leases which by nature and content do not deviate from ordinary operating business needs. The leases cover buildings, production plants and other equipment.

Legal proceedings pending

Certain claims have been raised against DuPont Nutrition Biosciences ApS. In the opinion of management, the outcome of these proceedings will not have any material effect on the financial position of DuPont Nutrition Biosciences ApS.

Ongoing tax audits

The Danish tax authorities have started an audit of the taxable income statements and transfer pricing covering the years 2006/07 to 2010/11. SKAT has suggested a material increase in the taxable income for part of the period under audit. Dupont Nutrition Biosciences ApS does not agree to the suggested increases, furthermore the audit is not yet finalized, thus no final conclusion has been reached. Based on this, we have included the audit as a contingent liability in the 2015 annual report .

18 Related parties and ownership

The Company is a wholly owned subsidiary of DuPont Denmark Holding ApS, Copenhagen, Denmark (controlling influence). The ultimate Parent Company in which the Company is included as a subsidiary is E.I. DuPont de Nemours and Company, Delaware, USA. This company and its subsidiaries are considered related parties through the ownership of the Company.

Transactions

Purchase/sale of goods from/to related parties has been effected at arm's length.

Notes to the Annual Report

19 Accounting Policies

The Annual Report of DuPont Nutrition Biosciences ApS has been prepared in accordance with the provisions of the Danish Financial Statements Act for large class C enterprises.

The annual report is presented in Danish kroner (DKK_m).

In accordance with section 112 (1) of the Danish Financial Statements Act no consolidated statement has been prepared. The financial statements of the Company and subsidiaries are part of the consolidated financial statements of E.I. DuPont de Nemours and Company, Delaware, USA.

The Group Annual report for E.I DuPont de Nemours and Company may be obtained at www.dupont.com

The accounting policies applied remain unchanged from previous years.

Recognition and measurement

Assets and liabilities are initially measured at cost. Subsequently, assets and liabilities are measured as described for each item below.

Recognition and measurement take into account predictable losses and risks occurring before the presentation of the Annual Report, which confirm or invalidate affairs and conditions existing at the balance sheet date.

Currency translation

Transactions in foreign currencies are translated during the year at the exchange rate at the dates of the transaction. Gains and losses arising due to differences between the transaction date and the rates of the date of the payment are recognised as financial income and expenses in the income statement.

Receivables, payables and other monetary items in foreign currencies that have not been settled at the balance sheet date are translated at the exchange rates at the balance sheet date. Any differences between the exchange rates at the balance sheet date and the transaction date rates are recognised as financial income and expenses in the income statement.

Income statement

Revenue

Revenue comprises invoiced sales less returned goods, bonuses and discounts granted in connection with sales. Sale of goods is recognised when the goods have been delivered and ownership and risk have passed to the buyer.

Cost of sales

Cost of sales includes raw materials, consumables, direct labour and indirect production costs such as maintenance and depreciation of production plant as well as administration and plant management.

Research and development expenses

Research and development expenses include costs, salaries and depreciation directly or indirectly attributable to research and development activities. Research expenses are recognised in the income statement in the year in which they are incurred. Clearly defined and identifiable development projects in which the technical degree of exploitation, adequate resources and potential market or development possibility in the enterprise are recognisable, and where it is the intention to produce, market or use the project, are recognised in intangibles where a correlation exists between the costs incurred and future earnings. Lack of regulatory approval, customer approvals and other uncertainties often imply that the requirements for recognition as an asset have not been met and that development expenses are consequently expensed when incurred.

Notes to the Annual Report

19 Accounting Policies (continued)

Sales and distribution expenses

Sales and distribution expenses comprise the salary expenses for sales personnel, advertising and exhibition expenses, depreciation and other indirect expenses.

Administrative expenses

Administrative expenses comprise the expenses of the administrative staff and management as well as depreciation and other indirect expenses.

Other operating income

Other operating income comprises income of a secondary nature in relation to the activities, including gains on the sale of intangible and tangible fixed assets.

Other operating expenses

Other operating expenses comprise expenses of a secondary nature in relation to the activities, including losses on the sale of intangible and tangible fixed assets.

Income from investments in subsidiaries

Income from investments in subsidiaries comprises gain/loss on sale of shares, dividends and writedowns. Dividends are recognised when the right to receive dividends has been approved by the relevant company bodies. To the extent that distributed dividends exceed the accumulated earnings after acquisition, dividends are recognised as writedown of the cost of the investment.

Financial income and expenses

Financial income and expenses include interest income, interest expenses, commission for committed facilities, borrowing expenses, amortisation of financial assets and liabilities, expenses incurred on finance leases and value adjustments, including fair value adjustments of derivative financial instruments not concluded for hedging of future transactions.

Corporation tax and deferred tax

Tax for the year consists of current tax for the year and deferred tax for the year. The tax attributable to the profit for the year is recognised in the income statement, whereas the tax attributable to equity entries is recognised directly in equity.

Deferred tax is measured under the balance sheet liability method in respect of all temporary differences between the carrying amount and the tax base of assets and liabilities. Deferred tax assets, including the tax base of tax loss carry-forwards, are measured at the value at which the asset is expected to be realised, either by elimination in tax on future earnings or by set-off against deferred tax liabilities.

DuPont Nutrition Biosciences ApS is jointly taxed with all Danish subsidiaries. Current Danish corporation tax is divided between the jointly taxed enterprises relative to their taxable income. Withholding taxes relating to dividends from subsidiaries outside Denmark are recognised in the year in which the dividend is declared.

Notes to the Annual Report

19 Accounting Policies (continued)

Balance Sheet

Intangible fixed assets

Intangible fixed assets are measured at cost less accumulated amortisation and accumulated impairment losses. Amortisation is made on a straight-line basis over the estimated useful lives of the assets.

Amortisation period:

Patents, licences and other intellectual property rights	up to 20 years
Software	up to 5 years

The amortisation periods are determined on the basis of management's experience in the enterprise's business areas and reflect in the opinion of management the best estimate of the economic useful lives of the assets.

Tangible fixed assets

Tangible fixed assets are measured at cost less accumulated depreciation and writedowns. Cost of tangible fixed assets comprises purchase price and costs directly attributable to making the asset capable of operating in the intended manner. Costs of self-constructed assets are determined using the same principles as for acquired assets.

Tangible fixed assets are depreciated on a straight-line basis over the estimated useful lives of the assets. Depreciation is initiated when the assets are deemed to be ready for use. Land is not depreciated.

Depreciation period:

Buildings	20-40 years
Plant and machinery	10-20 years
Fixtures, fittings, tools and equipment	3-7 years

The basis of depreciation is determined subject to the residual value of the asset. The residual value is determined at the date of acquisition and reviewed annually along with the useful life.

Lease payments under operating leases are accrued and recognised in the income statement as operating expenditure over the lease term.

The gain or loss arising on the disposal or retirement of an item of tangible fixed assets is determined as the difference between the sales proceeds and the carrying amount of the asset and is recognised in the income statement.

Investments in subsidiaries and associates

Investments in subsidiaries and associates are measured at cost less writedowns. To the extent that distributed dividends exceed the accumulated earnings after acquisition, dividends are recognised as writedown of the cost of the investment.

Other investments and securities

Investments and securities which comprise venture investments and listed and unlisted investments, are initially measured at cost and subsequently at fair value. Adjustment at fair value are recognised in the income statement as financial item. Adjustments include dividend income.

Other long-term receivables are initially measured at cost and subsequently at amortised cost or a lower value subject to individual assessment of loss.

Notes to the Annual Report

19 Accounting Policies (continued)

Impairment of fixed assets

At year-end the carrying amounts of tangible and intangible fixed assets with definite useful lives are reviewed to determine any indication of impairment. In the case of such indication, the recoverable amount of the asset is estimated in order to determine the extent of any impairment loss.

Where the asset does not generate cash flows that are deemed to be independent of other assets, an estimate is made of the recoverable amount of the unit to which the asset belongs. The recoverable amount is determined at the higher of the fair value less selling cost and the value in use. In the determination of value in use, estimated future cash flows are discounted by a discount rate reflecting market assessments of the time value of money and special risks associated with the asset for which adjustments have not been made in the estimated future cash flows.

Where the recoverable amount of the asset or unit is estimated to be lower than the carrying amount, the carrying amount is written down to the recoverable amount. Impairment losses are recognised in the income statement.

Financial fixed assets that are not measured at fair value are assessed at the end of the reporting period to determine if any objective indicators exist that an asset or group of assets has been impaired. In that case, the recoverable amount of the asset is determined and where lower than the carrying amount is written down to the recoverable amount.

Inventories

Inventories are recognised on a first-in/first-out (FIFO) basis and measured at cost. Where the cost exceeds the net realisable value, a writedown to this lower value is performed. Cost includes raw materials, consumables, direct labour and indirect production costs such as maintenance and depreciation of production plant and operations as well as administration and plant management. Obsolete items, including slow-moving items, are written down to net realisable value.

Receivables

Receivables are recognised in the balance sheet at the lower of amortised cost and net realisable value, which corresponds to nominal value less provisions for bad debts. Provisions for bad debts are determined on the basis of an individual assessment of each receivable.

Prepayments and deferred income

Prepayments include expenses incurred in respect of subsequent financial years.

Equity and treasury shares

Dividends are recognised as a liability at the date of adoption at the annual general meeting. In the consolidated annual accounts proposed dividend payments for the financial year are disclosed in a note to equity. Acquisition and sale considerations for treasury shares are recognised in equity.

Notes to the Annual Report

19 Accounting Policies (continued)

Liabilities

Liabilities are measured at amortised cost, substantially corresponding to nominal value.

Statement of cash flows

No cash flow statement is prepared with reference to the exemption provisions of section 86(4) of the Danish Financial statements Act. The cash flow of DuPont Nutrition Biosciences ApS are included in the consolidated financial statement of E.I. DuPont de Nemours and Company, Delaware, USA.

Financial ratios

The financial ratios have been calculated as follows:

$$\text{Profit margin} = \frac{\text{Operating Profit} \times 100}{\text{Revenue}}$$

$$\text{Return on net assets} = \frac{\text{Operating Profit} \times 100}{\text{Total assets}}$$

$$\text{Solvency ratio} = \frac{\text{Equity at year end} \times 100}{\text{Total assets}}$$

$$\text{Return on equity} = \frac{\text{Net Profit for the period} \times 100}{\text{Average equity}}$$